Benchmarking Blockbusters: Identifying winning products and therapy areas to 2008

Introduction

Developing blockbuster products has long been the focus of pharmaceutical companies and company reliance upon blockbuster revenue continues to increase on a yearly basis. However, with blockbuster sales growth forecast to slow considerably past 2005, pharmaceutical companies are under increasing pressure to meet investor expectation for the double-digit growth to which they have grown accustomed. 

Scope

Global analysis of historical and forecast changes in the blockbuster market across 12 therapy areas 

Detailed profiles of current and future blockbusters detailing key issues likely to impact product success between 2002 and 2008 

Analysis of the top 17 companies' blockbuster portfolios examining current and future share of blockbuster sales 

Sales forecasts for more than 130 products (blockbuster $1 billion plus and high earning $600-$999m) between 2002-08 

Report Highlights

Between 2002-08, sales of blockbuster products are forecast to rise from $116,408m to $158,046m. Company reliance on blockbuster revenues has increased since 2000. Between 2000-02, total blockbuster revenue as a percentage of total ethical revenues has increased from 40 per cent to 45.6 per cent. 

Cardiovascular and CNS products are forecast to dominate the blockbuster market: by 2008, attributed sales forecast to reach $67,810m accounting for 43 per cent of total blockbuster sales. 

The oncology therapy area is forecast to undergo the strongest sales growth. Sales are forecast to rise from the $6,484m in 2002 to $18,769m in 2008. 

Reasons to Purchase

Identify revenue opportunities by understanding the dynamics of the current and future blockbuster market 

Develop effective business development strategies by determining which therapy areas pose the greatest potential in revenue growth 

Develop proactive strategies by determining the threat posed to current revenues streams by new products with blockbuster potential 

Publisher: Datamonitor Drug Discovery Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Drug_Discovery.html#a595